Home » Personnel » CV and Publications

CV and Publications

Full Prof. Abraham Zangen

 

Prof. Abraham Zangen

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

Tel: +972-8-6472646 (office) 972-8-647-9180 / 2661 (lab)

Fax: 972-8-646 1713; Email: azangen@bgu.ac.il

 

Education

B.Sc. – 1988-1992 – The Hebrew University, Pharmacology

M.Sc. – 1994-1995 – Bar-Ilan University, Life Sciences

Ph.D. – 1996-1999 – Bar-Ilan University, Life Sciences

Title of thesis: Psychophysiological aspects of the action mechanism of antidepressant drugs.

Postdoctoral Training (2000-2003, NIH):

1. Opioids and cannabinoids in the brain reward circuitry

2. Transcranial Magnetic stimulation of the brain reward circuitry.

 

Employment History

2015-present: Full Professor, Dept of Life Science, Ben-Gurion University

2012-2015: Associate Professor, Dept of Life Science, Ben-Gurion University, Israel

2010-2012: Associate Professor, Dept of Neurobiology, The Weizmann Institute, Israel

2003-2010: Senior Scientist, Dept of Neurobiology, The Weizmann Institute, Israel

2000-2003: Postdoctoral Fellowship, National Institute on Drug Abuse (NIDA), NIH, USA

1994-1999: Research and Teaching Assistant (as a Ph.D. student), Bar-Ilan University, Israel

Professional Activities

2003-Present: Head of research laboratory (Neuroscience, Brain Stimulation),

2003-Present: Scientific Founder and Consultant for Brainsway.

Positions in academic administration

2014-present: Animal care committee of research animals facilities at BGU

2013-2016: Steering committee of the Zlotowski Center for Neuroscience, BGU

2013-present: Teaching programs committee of the Brain-Research school in BGU

2012-present: Chairman of the PsychoBiology Brain Studies Program, BGU

2007-8: Students acceptance committee, The Weizmann Institute of Science, Israel

Significant professional consulting

2003-present: Reviewing for journals: J. Neurosci., Biological Psychiatry, J. Neurochemistry, Molecular Psychiatry, PNAS, Brain Stimulation, Neuropsychopharmacology, Brain research, Psychopharmacology, Neurosci & Biobehavioral Rev., Eur. J. Neurosci., J. Comp. Neurosci., Arch Gen Psych.

2008: Consultant for the international safety guidelines of transcranial magnetic stimulation

2003-present: Founder and Scientific Consultant for Brainsway Inc.
 

Educational activities

Chairman of the PsychoBiology Brain Studies Program, Ben-Gurion University

Full Courses taught

  1. The Brain Reward System – M.Sc. and Ph.D. students – The Weizmann Institute of Science
  2. Neurobiology of drug addiction – M.Sc. and Ph.D. students – Ben-Gurion University
  3. Psychopharmacology- B.Sc. students – Ben-Gurion University

Research students and postdoctoral fellows

2003-2008, Dino Levy, Ph.D. student, The Weizmann Institute of Science

2003-2008, Roman Gersner, Ph.D. student, The Weizmann Institute

2004-2006, Alon Amir, M.Sc. student, The Weizmann Institute

2004-2008, Maytal Shabat-Simon, Ph.D. student, The Weizmann Institute, jointly supervised

2004-2010, Yaron Pen, Ph.D. student, The Weizmann Institute with Prof. Moshe Rehavi from Tel Aviv University

2004-2011, Dekel Taliaz, M.Sc. and Ph.D. student, The Weizmann Institute

2005-2006, Ayelet Katzir, M.Sc. student, The Weizmann Institute

2005-2007, Erika Toth, Postdoctoral fellow, The Weizmann Institute

2005-2006, Irit Akirav, Postdoctoral fellow, The Weizmann Institute

2005-2014, Noam Barnea Yigael, M.Sc.&Ph.D. student, Weizmann Institute & Ben-Gurion University (M.Sc. Jointly supervised with Prof. Gal Yadid from Bar-Ilan University)

2006-present, Michal Grubenger, Ph.D. student, Weizmann Institute and Ben-Gurion University, Jointly supervised with Prof. Talma Hendler from Tel Aviv University

2007-2012, Hagar Saida, Ph.D. student, The Weizmann Institute and Ben-Gurion University, jointly supervised with Prof. Benjamin Sredni from Bar-Ilan University

2008-2010, Liraz Kedar, M.Sc. student, The Weizmann Institute

2008-2014, Noga Karp, Ph.D. student, The Weizmann Institute

2009-2011, Roman Gersner, Postdoctoral Fellow, The Weizmann Institute

2011-2012, Dekel Taliaz, Postdoctoral Fellow, Weizmann Institute & Ben-Gurion University

2011-present, Itay Hadas, PhD student, Ben-Gurion University

2011-2014, Amit Shai, M.Sc. student, Ben-Gurion University

2012-2015, Inna Goldenberg, M.Sc. student, Ben-Gurion University

2012-present, Hamutal Cohen, Ph.D. student, Ben-Gurion University

2013-present, Lihi Bukovsa, M.Sc. student, Ben-Gurion University

2013-present, Yafit Hershler, Postdoctoral fellow, Ben-Gurion University

2014-2015, Dror Cohen, Postdoctoral fellow, Ben-Gurion University

2014-present, Noam Barnea Yigael, Postdoctoral fellow, Ben-Gurion University

2014-present, Samuel Zibman, Postdoctoral fellow, Ben-Gurion University

2014-present, Sagi Gottfried, M.Sc. student, Ben-Gurion University

2015-present, Amir Avnit, Ph.D. student, Ben-Gurion University

2018-present, Lior Kafri, M.Sc. student, Ben-Gurion University

2018-present, Guy Baz, M.Sc. student, Ben-Gurion University

2016-present, Yaniv Paz, Ph.D. student, Ben-Gurion University

 

Awards, Citations, Honors, Fellowships

1998 – The Israel Society for Biological Psychiatry Award for young researcher.

1998The Aharon Katzir Prize of Excellence for Ph.D. studies.

1999 – The Israeli Society for Biological Psychiatry Annual Prize

2000 – Fulbright Post-doctoral Fellowship

2000-2003 – Fogarty Post-doctoral Fellowship, (NIH, Fogarty Foundation).

2003 – NIH FARE (Fellows Award for Research Excellence) award.

2005 – INRC award for young scientists. Presenting INRC in the NIDA “Frontiers of Addiction” Mini-Convention at the Society for Neuroscience annual meeting of 2005.

2007 – Medical Futures Innovation Award, 2007.  Granted for developing transcranial magnetic stimulation of deep brain regions.  London, June, 2007.

2009 – The annual prize of the Israeli Society for Biological Psychiatry, provided to my Ph.D. student for our jointly submitted paper “Knockdown of BDNF in specific brain sites causes depressive behavior and reduces neurogenesis”

2010 – Sieratzki-Korczyn Prize for Advances in Neuroscience, Tel Aviv, Provided by the Tel-Aviv University.

2012 – Complex medical engineering award, CME 2012, Kobe, Japan.

2015 – The Juludan Prize for applications of natural sciences in medicine, Technion 2016, Israel

 

Synopsis of research and achievements

I am a Full Professor, the head of the brain stimulation and behavior lab and the chair of the psychobiology brain program at the Ben-Gurion University in Israel.  Following my first degree in pharmacology in the medical school of the Hebrew University (1988-1992) and academic service in the IDF, I turned to brain research. My Ph.D. studies (1996-2000) suggested a direct role for the brain reward system in the mechanism of antidepressant action. During my postdoctoral studies at the National Institute on Drug Abuse, NIH (2000-2003) with Roy Wise I identified specific brain sites that mediate the rewarding effect of neuropeptides and drugs of abuse.  I also studied mechanisms of brain stimulation reward and developed a special coil allowing deep transcranial magnetic stimulation (DTMS) in humans with Mark Hallett (NINDS, NIH).  In 2003 I joined the Weizmann Institute as a Senior Scientist in the department of neurobiology and promoted to the rank of Associate Professor in 2010. In 2012 I joined the Ben-Gurion University and in 2015 was promoted to the rank of Full Professor. Since my return to Israel I am studying mechanisms of altered neuroplasticity in depression, addiction and impaired attention, and the effects of repeated brain stimulation on markers for neuroplasticity and on behavioral outcomes in animal models for depression and addiction.  I am also studying physiological outcomes and the potential effectiveness of the unique DTMS coil I developed for the treatment of depression, addiction and ADHD. The device I developed for the treatment of depression and OCD was already approved by the FDA and other regulatory bodies and treated over 50,000 patients, while other versions of the device are being tested for their efficacy in other psychiatric and neurological disorders. My early work in this field led to establishment of Brainsway, a company that commercializes the coils I developed with my colleagues.

I have published over 150 peer-reviewed articles, reviews and book chapters. 25 of the articles were cited already over 100 times in peer reviewed articles. My current H-factor is 49.  My scientific work was rewarded with 12 different personal prizes including the Medical Futures Innovation Award in London (2007), the Sieratzki-Korczyn prize for advances in neurosciences (2010), the CME award (2012), The Joludan Prize (2015) and I have received several distinguished research grants including NIH, European Horizon 2020, ISF, and BSF.

 

Scientific Publications

H-Index: 49 (full list at:  https://scholar.google.co.il/citations?user=kgHy4MQAAAAJ&hl=en )

Book Chapters

  1. Roth Y. and Zangen A. (2006) Transcranial magnetic stimulation of deep brain regions. Biomedical Engineering Fundamentals (ed. Joseph D. Bronzino) chapter 37 pp 1-25 (CRC Press, Taylor & Francis 3rd ed., NY USA, 2006).
  2. Roth Y., Padberg F. and Zangen A. (2007) Transcranial magnetic stimulation of deep brain regions: Principles and methods. In Advances in Biological Psychiatry (Transcranial brain stimulation for treatment of psychiatric disorders, Eds: Marcolin and Padberg) 23 pp 204-224 (Karger Publishers Zürich, Switzerland, 2007).
  3. Feil J. and Zangen A. (2013) Brain stimulation in the study of addiction. In Brain Stimulation, Handbook of Neurology (Eds: Lozano A and Hallett M), 116 pp 613-30 (Elsevier, 2013).
  4. Roth Y. and Zangen A. (2013) Basic Principles and methodological aspects of transcranial magnetic stimulation. In Frontiers in Neuroscience book series (Series editors: Sidney A. Simon & Miguel A. L. Nicolelis): Transcranial Brain Stimulation (Eds: Miniussi C, Paulus W, Rossini PM) pp 1-39 (CRC Press / Taylor & Francis Group London, 2013).
  5. Roth Y. and Zangen A. (2014) Reaching Deep Brain Structures: The H-Coils. In Neuromethods: Transcranial Magentic Stimulation (Eds: Rotenberg A, Horvath J and Pascual Leone A) 89 pp 57-69 (Humana Press / Springer, New York, 2014).
  6. Roth Y. and Zangen A. (2014) Protocol for Depression Treatment Utilizing H-Coil. In Neuromethods: Transcranial Magentic Stimulation (Eds: Rotenberg A, Horvath J and Pascual Leone A) 89 pp 313-337 (Humana Press / Springer, New York, 2014).
  7. Hadar A. and Zangen A. (2015) Brain stimulation as a novel technique for craving management and the treatment of Addiction. In Handbook on the Cognitive Neuroscience of Addiction (Ed: Wilson. S) pp 357-389 (Oxford, Wiley-Blackwell, 2015).

Peer reviewed articles in scientific journals (main articles included)

  1. Zangen A., Overstreet D.H. and Yadid G. (1997) High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: Normalization by chronic antidepressant treatment. Neurochem. 69:2477-2483.
  2. Zangen A. and Shainberg A. (1997) Thiamine deficiency in cardiac cells in culture. Biochem Pharmacol 54: 575-582.
  3. Zangen A., Botzer D., Zangen R. and Shainberg A. (1998) Furosemide and digoxin inhibit thiamine uptake in cardiac cells. J. Pharmacol. 361:151-155.
  4. Zangen A., Herzberg U., Vogel Z. and Yadid G. (1998) Nociceptive stimulus induces release of endogenous -endorphin in the brain. Neuroscience 85:659-662.
  5. Serova L., Sabban E., Zangen A., Overstreet D.H. and Yadid G. (1998) Altered gene expression for catecholamine biosynthetic enzymes and stress response in rat genetic model of depression. Brain Res. 63:133-138.
  6. Zangen A., Overstreet D.H. and Yadid G. (1999) Increased catecholamine levels in specific brain regions of a rat model of depression: Normalization by chronic antidepressant treatment. Brain Res. 824:243-250.
  7. Zangen A., Nakash R. and Yadid G. (1999) Serotonin-mediated increases in extracellular -endorphin levels in the arcuate nucleus and nucleus accumbens: A microdialysis study. Neurochem. 73:2569-2574.
  8. Yadid G., Nakash R., Deri I., Grin T., Kinor N., Gispan I. and Zangen A. (2000) Elucidation of the neurobiology of depression: Insights from a novel genetic animal model. Neurobiol. 62:353-378.
  9. Yadid G., Zangen A., Dmitrochenko A., Overstreet D.H. and Zohar J. (2000) Screening for new antidepressants with fast onset and long lasting action. Drug Dev. Res. 50:392-399.
  10. Yadid G., Zangen A., Herzberg U., Nakash R. and Sagen J. (2000) Alterations in endogenous brain b-endorphin release by adrenal medullar transplants in the spinal cord. 23:709-716.
  11. Yadid G., Overstreet D.H. and Zangen A. (2001) Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression. Brain Res. 896:43-47.
  12. Zangen A., Nakash R., Overstreet D.H. and Yadid G. (2001) Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology 155:434-439.
  13. Shir Y., Zeltser R., Vatine J., Carmi G., Belfer I., Zangen A., Overstreet D.H. and Seltzer Z. (2001) Correlation of intact sensibility and neuropathic pain-related behaviors in rats. Pain 90:75-82.
  14. Woods A. and Zangen A. (2001) Direct chemical interaction between dynorphin and excitatory amino acids. Res. 26:395-400.
  15. Zangen A., Ikemoto S., Zadina J.E. and Wise R.A. (2002) Rewarding and psychomotor stimulant effects of endomorphin-1: Anteroposterior differences within the ventral tegmental area and lack of effect in nucleus accumbens. Neurosci. 22:7225-7233.
  16. Roth Y*, Zangen A*, and Hallett M. (2002) A Coil Design for Transcranial Magnetic Stimulation of Deep Brain Regions. Clin Neurophysiol, 19:361-370. (*equal contribution).
  17. Greenwell T., Zangen A., Martin-Schild S., Gerall A.A., Wise R.A. and Zadina J.E. (2002) Endomorphin-1 and -2 immunoreactive cells in the hypothalamus are labeled by fluorogold injections to the ventral tegmental area. Comp. Neurol.454:320-328.
  18. Zangen A., Nakash R., Overstreet D.H. and Yadid G. (2002) Impaired response of beta-endorphin to serotonin stimulation in a rat model of depression. Neuroscience 110:389-393.
  19. Zangen A and Hyodo K. (2002) Transcranial magnetic stimulation induces increases in extracellular levels of dopamine and glutamate in the nucleus accumbens. Neuroreport, 13:2401-2405.
  20. Roth-Deri I., Zangen , Aleli M., Goelman R.G., Peled G., Nakash R., Gispan-Herman I., Shaham Y. and Yadid G. (2003) Effect of experimenter-delivered and self-administered cocaine on extracellular beta-endorphin levels in the nucleus accumbens J. Neurochem. 84: 930-938.
  21. Zangen A. and Shalev U. (2003) Nucleus accumbens beta-endorphin levels are not elevated by brain stimulation reward but do increase with extinction. Eur J Neurosci. 17:1067-1072.
  22. Ikemoto S., Witkin B.M., Zangen A. and Wise R.A. (2004) Rewarding effects of AMPA administration into the supramammillary or posterior hypothalamic nuclei but not the ventral tegmental area. J Neurosci.  24:5758-5765.
  23. Solinas M., Zangen A., Thiriet N and Goldberg S.R. (2004) beta-Endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur J. Neurosci. 19:3183-3192.
  24. Gersner R., Dar D.E., Shabat-Simon M. and Zangen A. (2005) Behavioral analysis during the forced swim test using a joystick device. Neurosci. Meth 143:117-21.
  25. Butovsky E., Juknat A, Goncharov I., Elbaz J., Eilam R., Zangen A. and Vogel Z. (2005) In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem. 93:802-11.
  26. Zangen A., Roth Y., Voller B. and Hallett M. (2005) Transcranial Magnetic Stimulation of Deep Brain Regions: Evidence for Efficacy of the H-Coil. Neurophysiol. 116:775-9.
  27. Butovsky E., Juknat A., Elbaz J., Shabat-Simon M., Eilam R., Zangen A., Altstein M. and Vogel Z. (2006) Chronic exposure to Delta(9)-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol Cell Neurosci. 31:795-804.
  28. Zangen A., Solinas M., Ikemoto S., Goldberg S.R. and Wise R.A. (2006) Two brain sites for cannabinoid reward. Neurosci. 26:4901-4907.
  29. Roth Y., Amir A., Levkovitz Y. and Zangen A. (2007) Three-Dimensional Distribution of the Electric Field Induced in the Brain by Transcranial Magnetic Stimulation Using Figure-8 and Deep H-Coils. J Clin Neurophysiol. 24:31-38.
  30. Cooper A., Barnea-Ygael N., Levy D., Shaham Y. and Zangen A. (2007) A conflict rat model of cue-induced relapse to cocaine seeking. Psychopharmacology. 194:117-25.
  31. Levkovitz Y., Roth Y., Harel E.V., Braw Y., Sheer A. and Zangen A. (2007) Deep Transcranial Magnetic Stimulation: a randomized controlled safety and cognitive study. Neurophysiol, 118: 2730–2744.
  32. Levy D., Shabat-Simon M., Shalev U., Barnea-Ygael N., Cooper A. and Zangen A. (2007) Repeated electrical stimulation of reward-related brain regions affects cocaine but not “natural” reinforcement. Neurosci. 27; 14179-89.
  33. Toth E., Gersner R., Wilf-Yarkoni A., Raizel H., Dar D.E., Richter-Levin G., Levit O. and Zangen A. (2008) Age-dependent effects of chronic stress on brain plasticity and depressive behavior. Neurochem, 107: 522-32.
  34. Shabat-Simon M., Levy D., Amir A., Rehavi M. and Zangen A. (2008) Dissociation between the rewarding and the psychomotor sensitization effects of opioids: Different roles for AMPA receptors in the anterior and posterior portions of the ventral tegmental area. Neurosci, 28: 8406-16.
  35. Lewitus G.M., Wilf-Yarkoni A., Ziv Y., Shabat-Simon M., Gersner R., Zangen A. and Schwartz M. (2008) Vaccination as a novel approach for treating depressive behavior. Biol Psychiatry, 65:283-8.
  36. Amiaz R., Levy D., Vainiger D., Grunhaus L. and Zangen A. (2009) Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction, 104: 653-660.
  37. Gersner R., Kiwkowitz M. and Zangen A. (2009) A novel automated analysis of limbs’ activity in the forced swim test. Neurosci. Meth. 180: 82-86.
  38. Stehberg J., Levy D. and Zangen A. (2009) Impairment of aversive memory reconsolidation by localized intracranial electrical stimulation. Eur J. Neurosci, 29: 964-9.
  39. Huang Y., Sommer M., Thickbroom G., Pascual-Leonne A., Paulus W., Classen J., Peterchev A.V., Zangen A. and Yoshikazu U. (2009) Consensus: New methodologies for brain stimulation. Brain Stimulation 2: 2-13.
  40. Salvador R., Miranda P.C., Roth Y. and Zangen A. (2009) High permeability cores to optimize the stimulation of deeply located brain regions using transcranial magnetic stimulation. Med. Biol. 54: 3113-28.
  41. Levkovitz Y., Harel E.V.,Roth Y., Braw Y., Sheer A. , Katz L., Gersner R. and Zangen A. (2009) Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. Brain Stimulation 2: 188-200.
  42. Rossi S., Hallett M., Rossini P.M., Pascual-Leone A. and Safety of TMS Consensus Group (2009). Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 120:2008-2039.
  43. Roth Y., Pell G. and Zangen A. (2010) Motor evoked potential latency, motor threshold and electric field measurements as indices of transcranial magnetic stimulation depth. Clin Neuropysiol. 121:255-8.
  44. Taliaz , Stall N., Dar D.E. and Zangen A. (2010) Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol. Psychiatry, 15: 80-92 Selected for the Cover of the January 2010 Issue.
  45. Gersner R., Toth E., Isserless I. and Zangen A. (2010) Site-specific antidepressant effects of repeated subconvulsive electrical stimulation: potential role of brain-derived neurotrophic factor. Psychiatry, 67: 125-132.
  46. Isserles M., Rosenberg O., Dannon P., Lerer B. and Zangen A. (2011) Cognitive emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcomes. J. Affect Disord. 128: 235-242.
  47. Harel E.V., Zangen A., Roth Y., Reti I., Braw Y., Levkovitz Y. (2011) H-coil repetitive transcranial magnetic stimulation for the treatment of bipolar depression: an add-on, safety and feasibility study. World J Biol Psychiatry. 12:119-126.
  48. Levkovitz Y., Rabany L., Harel E.V. and Zangen A. (2011) Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: A feasibility study. Int J Neuropsychopharmacol. 14:991-6.
  49. Levkovitz Y., Sheer A., Harel E.V., Katz L.N., Most D., Zangen A. and Isserles M. (2011) Differential effects of deep TMS of the prefrontal cortex on apathy and depression. Brain Stimulation. 4:266-74.
  50. Taliaz , Loya A., Gersner R., Haramati S., Chen A. and Zangen A. (2011) Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor.  J. Neurosci, 31: 4475-4483.
  51. Rosenberg O., Roth Y., Kotler M., Zangen , Dannon P. (2011) Deep transcranial magnetic stimulation for the treatment of auditory hallucinations: a preliminary open-label study. Ann Gen Psychiatry. 10:3.
  52. Gersner R., Kravetz E., Feil J., Pell G. and Zangen A. (2011) Long-term effects of repetitive transcranial magnetic stimulation on markers for neuroplasticity: differential outcomes in anesthetized and awake animals. J Neurosci. 31:7521-6.
  53. Lev-Ran S., Shamay-Tsoory S.G., Zangen A. and Levkovitz Y. (2011) Transcranial magnetic stimulation of the ventromedial prefrontal cortex impairs theory of mind learning. Psychiatry 27:285-9.
  54. Enticott P.G., Kennedy H.A., Zangen A. and Fitzgerald P.B. (2011) Deep repetitive transcranial magnetic stimulation associated with improved social functioning in a young woman with an autism spectrum disorder. J ECT. 27:41-3.
  55. Barnea-Ygael N., Yadid G., Yaka R., Ben Shachar O. and Zangen A. (2012) Cue-induced reinstatement of cocaine seeking in the rat “conflict model”: effect of prolonged home-cage confinement. Psychopharmacology 219:875-83.
  56. Krause L., Enticott P.G., Zangen A. and Fitzgerald P.B. (2012) The role of medial prefrontal cortex in theory of mind: a deep rTMS study. Behav Brain Res. 228:87-90.
  57. Rosenberg O., Gersner R., Klein L.D., Kotler M., Zangen A. and Dannon P. (2012) Deep transcranial magnetic stimulation add-on for the treatment of auditory hallucinations: a double-blind study. Ann Gen Psychiatry 2012 11:13.
  58. Isserles M., Shalev A.Y., Roth Y., Peri T., Kutz I., Zlotnick E. and Zangen A. (2013) Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in post-traumatic stress disorder – a pilot study. Brain Stimul 6:377-83.
  59. Taliaz D., Nagaraj V., Haramati S., Chen A. and Zangen A. (2013) Altered brain-derived neurotrophic factor expression in the ventral tegmental area, but not in the hippocampus, is essential for antidepressant-like effects of electroconvulsive therapy. Biol Psychiatry. 74:305-12.
  60. Onesti E. , Gabriele M. , Cambieri C., Ceccanti M., Raccah R., Di Stefano G., Biasiotta A., Truini A., Zangen A. and Inghilleri M.  (2013) H-coil repetitive transcranial magnetic stimulation for pain relief in patients with diabetic neuropathy.  Eur J Pain. 17:1347-56.
  61. Harel E.V., Rabany L., Deutsch L., Bloch Y., Zangen A. and Levkovitz Y. (2014) H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study. World J Biol Psychiatry 15:298-306.
  62. Roth Y., Pell G.S., Chistyakov A.V., Sinai A., Zangen A., Zaaroor M. (2014) Motor cortex activation by H-coil and figure-8 coil at different depths. Combined motor threshold and electric field distribution study. Clin Neurophysiol.125:336-43.
  63. Roth , Levkovitz Y., Pell G.S., Ankry M. and  Zangen A. (2014) Safety and characterization of a novel multi-channel TMS stimulator.  Brain Stimulation 7:194-205.
  64. Gersner R., Gal R., Levit O., Moshe H. and Zangen A. (2014) Inherited behaviors, BDNF expression and response to treatment in a novel multifactorial rat model for depression. J. Neuropsychopharm 17:945-55.
  65. Gaede G., Hellweg R., Zimmermann H., Brandt A.U., Dörr J., Bellmann-Strobl J., Zangen A., Paul F and Pfueller C.F. (2014) Effects of deep repetitive transcranial magnetic stimulation on brain-derived neurotrophic factor serum concentration in healthy volunteers. Neuropsychobiology 69:112-9.
  66. Enticott PG, Fitzgibbon BM, Kennedy HA, Arnold SL, Elliot D, Peachey A, Zangen A and Fitzgerald PB. (2014) A double-blind, randomized trial of deep repetitive transcranial magnetic stimulation (rTMS) for autism spectrum disorder. Brain Stimul. 7:206-11.
  67. Zilkha N, Feigin E , Barnea-Ygael N and Zangen A (2014) Induction of depressive-like effects by subchronic exposure to cocaine or heroin in laboratory rats. Neurochem. 130:575-82.
  68. Dinur-Klein , Dannon P., Hadar A., Rosenberg O., Roth Y., Kotler M. and Zangen A.   (2014) Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: A prospective, randomized controlled trial. Biol. Psychiatry 76:742-9.
  69. Berlim MT, Van den Eynde F, Tovar-Perdomo S, Chachamovich E, Zangen A and Turecki G. (2014) Augmenting antidepressants with deep transcranial magnetic stimulation (DTMS) in treatment-resistant major depression. World J Biol Psychiatry 15:570-8.
  70. Rapinesi C, Curto M, Kotzalidis GD, Del Casale A, Serata D, Ferri VR, Di Pietro S, Scatena P, Bersani FS, Raccah RN, Digiacomantonio V, Ferracuti S, Bersani G, Zangen A, Angeletti G, Girardi P (2014) Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): A 6-month, open label, follow-up study. J Affect Disord. 174:57-63.
  71. Harvey P.O., Van den Eynde F., Zangen A., Berlim M.T. (2015) Neural correlates of clinical improvement after deep transcranial magnetic stimulation (DTMS) for treatment-resistant depression: a case report using functional magnetic resonance imaging.  Neurocase, 21:16-22.
  72. Girardi P, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V, Ferri VR, Ferracuti S, Zangen A and Angeletti G. (2015) Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: A comparison with standard treatment. World J Biol Psychiatry 16:66-73.
  73. Pell GS, Roth Y. and Zangen A. (2015) Realistic shape head model and spherical model as methods for TMS coil characterization. Clin Neurophysiol. 126:1455-6
  74. Levkovitz Y., Isserles M., Padberg F., Lisanby S.H., Bystritsky A., Xia G., Tendler A., Daskalakis Z.J., Winston J.L., Dannon P., Hafez H.M., Reti I.M., Morales O.G., Schlaepfer T.E., Hollander E., Berman J.A., Husain M.M., Sofer U., Stein A., Adler S., Deutsch L., Deutsch F., Roth Y., George M.S. and Zangen A (2015) Efficacy and safety of deep transcranial magnetic stimulation for major depression: A prospective, multicenter, randomized, controlled trial.  World Psychiatry 14:64-73.
  75. Ceccanti M, Inghilleri M, Attilia ML, Raccah R, Fiore M, Zangen A and Ceccanti M (2015) Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study. J. Physiol Pharmacol. 93:283-90.
  76. Gruberger M, Levkovitz Y, Hendler T, Harel EV, Harari H, Ben Simon E, Sharon H and Zangen A (2015) I think therefore I am: Rest-related prefrontal cortex neural activity is involved in generating the sense of self. Conscious Cogn.  33:414-421.
  77. Pushparaj A, Kim AS, Musiol M, Zangen A, Daskalakis ZJ, Zack M, Winstanley CA, Le Foll B. (2015) Differential Involvement of the Agranular vs Granular Insular Cortex in the Acquisition and Performance of Choice Behavior in a Rodent Gambling Task. 40:2832-42.
  78. Kedzior K.K, Gellersen H.M, Roth Y and Zangen A (2015) Acute reduction in anxiety after deep transcranial magnetic stimulation (DTMS) in unipolar major depression- a systematic review and meta-analysis. Psychiatry Res. 230: 971-4
  79. Barnea-Ygael N., Gal R. and Zangen A. (2016) Chronic cocaine administration induces long-term impairment in the drive to obtain natural reinforcers in high- but not low-demanding tasks.  Addiction Biology. 21:294-303
  80. Moshe H, Gal R, Aluagon U, Barnea-Ygael N and Zangen A (2016) Prelimbic stimulation ameliorates depressive-like behaviors and increases regional BDNF expression in a novel drug-resistant animal model of depression. Brain Stimulation 9:243-50.
  81. Naim-Feil, J., Bradshaw, J. L., Sheppard, D. M., Rosenberg, O., Levkovitz, Y., Dannon, P., and Zangen, A. (2016). Neuromodulation of Attentional Control in Major Depression: A Pilot Deep TMS Study. Neural Plasticity, 2016:5760141.
  82. Hadas I, Gal R, Bokovza L, Meiran N, Feifel D and Zangen A. (2016) Exposure to salient, dynamic sensory stimuli during development increases distractibility in adulthood. Sci Rep. 6:21129.
  83. Fiocchi S, Longhi M, Ravazzani P, Roth Y, Zangen A and Parazzini M. Modelling of the electric field distribution in deep transcranial magnetic stimulation in the adolescence, in the adulthood, and in the old age. (2016) Comput Math Methods Med.
  84. Vazana U, Veksler R, Pell GS, Prager O, Fassler M, Chassidim Y, Roth Y, Shahar H, Zangen A, Raccah R, Onesti E, Ceccanti M, Colonnese C, Santoro A, Salvati M, D’Elia A, Nucciarelli V, Inghilleri M, Friedman A. (2016) Glutamate-Mediated Blood-Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery. J Neurosci. 36:7727-39.
  85. Gersner R, Oberman L, Sanchez MJ, Chiriboga N, Kaye HL, Pascual-Leone A, Libenson M, Roth Y, Zangen A, Rotenberg A. H-coil repetitive transcranial magnetic stimulation for treatment of temporal lobe epilepsy: A case report. (2016) Epilepsy Behav Case Rep. 5:52-6.
  86. Gersner R, Dhamne SC, Zangen A, Pascual-Leone A, Rotenberg A. (2016) Bursts of high-frequency repetitive transcranial magnetic stimulation (rTMS), together with lorazepam, suppress seizures in a rat kainate status epilepticus model. Epilepsy Behav. 62:136-9.
  87. Tendler A, Barnea Ygael N, Roth Y and Zangen A. Deep transcranial magnetic stimulation (dTMS) – beyond depression (2016) Expert Rev Med Devices. 13:987-1000.
  88. Tendler A, Roth Y, Barnea-Ygael N and Zangen A. (2017) How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression. J Vis Exp. Jan 23;(119). doi: 10.3791/55100.
  89. Paz Y, Friedwald K, Levkovitz Y, Zangen A, Alyagon U, Nitzan U, Segev A, Maoz H, Koubi M, Bloch Y. (2017) Randomised sham-controlled study of high-frequency bilateral deep transcranial magnetic stimulation (dTMS) to treat adult attention hyperactive disorder (ADHD): Negative results. World J Biol Psychiatry 31:1-6.
  90. Tendler A, Sisko E, Barnea-Ygael N, DeLuca M, Rodriguez N, Corbett-Methott S, Sutton J, and Zangen A (2017) Antidepressant remission to dTMS of the dmPFC and ACC in lateral PFC dTMS nonresponders: Case series. Brain Stimualation. 10:714-715.
  91. Parazzini M, Fiocchi S, Chiaramello E, Roth Y, Zangen A, Ravazzani P. (2017) Electric field estimation of deep transcranial magnetic stimulation clinically used for the treatment of neuropsychiatric disorders in anatomical head models. Med Eng Phys. 43:30-38.
  92. Yip AG, George MS, Tendler A, Roth Y, Zangen A, Carpenter LL. (2017) 61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. Brain Stimulation 10:847-849.
  93. Hadar A, Hadas I, Lazarovits A, Alyagon U, Eliraz D and Zangen A. (2017) Answering the missed call: Initial exploration of cognitive and electrophysiological changes associated with smartphone use and abuse. PLoS One. Jul 5;12(7):e0180094.
  94. Roth Y, Pell GS and Zangen A. (2017) Network Meta-analysis in Mental Health Research. JAMA Psychiatry. 74:851.
  95. Malik S, Jacobs M, Cho SS, Boileau I, Blumberger D, Heilig M, Wilson A, Daskalakis ZJ, Strafella AP, Zangen A, Le Foll B (2017) Deep TMS of the insula using the H-coil modulates dopamine release: a crossover [11C] PHNO-PET pilot trial in healthy humans. Brain Imaging Behav. doi: 10.1007/s11682-017-9800-1
  96. Carmi L, Alyagon U, Barnea-Ygael N, Zohar J, Dar R and Zangen A. (2018) Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. Brain Stimulation 11:158-165.
  97. Kaster TS, Daskalakis ZJ, Noda Y, Knyahnytska Y, Downar J, Rajji TK, Levkovitz Y, Zangen A, Butters MA, Mulsant BH, Blumberger DM, (2018). Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacology doi: 10.1038/s41386-018-0121-x.
  98. Martinez D, Urban N, Grassetti A, Chang D, Hu MC, Zangen A, Levin FR, Foltin R, Nunes EV (2018) Transcranial Magnetic Stimulation of Medial Prefrontal and Cingulate Cortices Reduces Cocaine Self-Administration: A Pilot Study. Front Psychiatry. 16;9:80.
  99. Chieffo R, Scopelliti G, Fichera M, Santangelo R, Guerrieri S, Zangen A, Comi G, Leocani L. (2018) Bi-hemispheric repetitive transcranial magnetic stimulation for upper limb motor recovery in chronic stroke: A feasibility study. Brain Stimul. 11:932-934.
  100. Tendler A, Gersner R, Roth Y and Zangen A. (2018) Alternate day dTMS combined with SSRIs for chronic treatment resistant depression: A prospective multicenter study. J Affect Disord. 240:130-136.
  101. Cohen, O. S., Rigbi, A., Yahalom, G., Warman-Alaluf, N., Nitsan, , Zangen, A., and Hassin-Baer, S. (2018). Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study. Journal of Clinical Neurophysiology, 35(2), 159-165.
  102. Rapinesi, C., Kotzalidis, G. D., Ferracuti, S., Girardi, N., Zangen, A., Sani, G., … and Del Casale, A. (2018). Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex in depressive episodes of patients with major depressive disorder, bipolar disorder I, and major depressive with alcohol use disorders. Neuroscience letters, 671, 128-132.
  103. Tendler, A., Roth, Y., and Zangen, A. (2018). Rate of inadvertently induced seizures with deep repetitive transcranial magnetic stimulation. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, 11(6), 1410-1414.
  104. Zibman, S., Daniel, E., Alyagon, U., Etkin, A., and Zangen, A. (2019). Interhemispheric cortico-cortical paired associative stimulation of the prefrontal cortex jointly modulates frontal asymmetry and emotional reactivity. Brain stimulation, 12(1), 139-147.

Invited reviews

  1. Dar D.E. and Zangen A. (2006) Recent advances in selective mu-opioid ligands as evaluated in animal models. CMS-CNS 6: 1-14.
  2. Zangen A. (2009) Rewiring Circuitry in Depression. Frontiers in Neuroscience, 3: 268-270.
  3. Feil J. and Zangen A. (2010) Brain stimulation in the study and treatment of addiction. Neurosci Biobehav Rev, 34: 559–574.
  4. Zangen A. (2010) Novel Perspectives on Drug Addiction and Reward Neurosci Biobehav Rev, Editorial 35:127-8.
  5. Pell GS., Roth Y. and Zangen A. (2011) Modulation of cortical excitability induced by repetitive transcranial magnetic stimulation: Influence of timing and geometrical parameters and underlying mechanisms. Neurobiol.  93:59-98.
  6. Gruberger M., Ben-Simon E., Levkovitz Y., Zangen A., Hendler T. (2011) Towards a neuroscience of mind-wandering. Front Hum Neurosci. 5:56.
  7. Vahabzadeh-Hagh A.M., Muller P.A., Gersner R., Zangen A. and Rotenberg A. (2012) Translational neuromodulation: Approximating human transcranial magnetic stimulation protocols in Neuromodulation 15:296-305.
  8. Zangen A. (2013) Studying schizophrenia as a neuroplastic disorder. Can J Psychiatry 58:84-5.
  9. Gorelick DA, Zangen A, George MS (2014). Transcranial magnetic stimulation in the treatment of substance addiction. Ann N Y Acad Sci. 1327:79-93.

Patents

  1. 2002 – Filed, 2007 – Issued. Zangen A, Roth Y, Miranda P, Wise RA, Hallett M (First inventor: Abraham Zangen): Coil for Transcranial Magnetic Stimulation of Deep Brain Regions. Approved 2007 in USA and Europe, 2008 in Australia, Japan, Israel, Canada and others.
  2. 2005 – Filed, 2010 – Issued – Zangen A, Roth Y, Hazani D, Miranda P, Hallett M: Transcranial magnetic stimulation system and methods. Approved 2011 in USA, Europe, Israel, Japan, Australia, Hong Kong, Canada.
  3. 2011 – Filed, 2015 – Issued. Zangen A, Roth Y, Hazani D, Miranda P, Hallett M: Systems and methods for controlling parameters of transcranial magnetic stimulation. USA, Europe, Israel, Australia, Japan.
  4. 2012 – Filed, 2017 – Issued. Pell G, Friedman A and Zangen A Method for opening blood brain barrier using transcranial magnetic stimulation. USA
  5. 2013 – Filed, 2016 – Issued. Zangen A, Roth Y, Central Base Coils for Deep Transcranial Magnetic Stimulation. USA
  6. 2013 – Filed, 2017 – Issued. Zangen A, Roth Y, Unilateral Coils for Deep Transcranial Magnetic Stimulation. USA
  7. 2016- Filed. Alyagon U, Zangen A, Pell G, Roth Y, Segal R, Geva A, Peremen Z, Shani-Hershkovitz S. Predicting Therapy Outcome. USA, Israel

 

Research Grants

Benozyio center for neurological diseases (Abraham Zangen –PI)

Electrophysiological alteration in the reward system during the development of cocaine addiction

Total amount 25,000 US $ (2005-2006).

BIAL foundation (PIs Abraham Zangen and Pedro Miranda).

Improvement of Transcranial Magnetic Stimulation (TMS) coils for Psychiatric Applications.

Total amount: 50,000 Euro (2005-2007)

National Inst. For Psychobiology (Abraham Zangen – PI)

The Efficacy of Chronic Electrical Stimulation of the Brain Reward System in the Treatment of Depressive Behavior.  Total amount: 18,000 US $ (2005-2007)

Rosenzweig-Coopersmith Foundation (Abraham Zangen – PI)

The brain reward system in depression and addiction.   Total amount: 80,000 US $ (2005-2008)

Brainsway (through Yeda at Weizmann) (Abraham Zangen –PI)

Brain stimulation effects in animal models for depression and addiction. Total amount: 50,000 US $ (2006-2008).

Israel Science Foundation (ISF) (Abraham Zangen – PI)

Role of Brain Derived Neurotrophic Factor (BDNF) within the Brain Reward System in Depressive Behavior. Evaluation by Localized BDNF Silencing. Total amount: 185,000 US $ (2006-2010).

NIH R21 grant (Abraham Zangen – PI)

A conflict model of relapse to drug use. Total amount: 216,000 US $ (2007-2009).

Teva (through Yeda at Weizmann) (Abraham Zangen –PI)

Evaluation of a cocaine antidote for prevention of relapse to cocaine use in animal models. Total $25,000 (2008).

Israel Anti-Drug association (Abraham Zangen –PI).

Transcranial Magnetic Stimulation as a novel approach to study and treat addiction.  Total amount 100,000 NIS (2008-2009).

Brainsway (through Yeda at Weizmann) (Abraham Zangen –PI)

Brain stimulation effects in animal models for depression and addiction. Total amount: 65,000 US $ (2008-2010).

Teva (through Yeda at Weizmann) (Abraham Zangen –PI)

Evaluation of a cocaine antidote for prevention of relapse to cocaine use in animal models. Total amount: 45,000 US $ (2009).

EU Global Research Award on Nicotine Addiction (GRAND) 2010 (Abraham Zangen – Co Investigator)

Does the insula control smoking-induced dopamine release? A brain simulation-imaging study in humans.  Total amount: 200,000 US $ (AZ part – 40,000 US $).

Israel Ministry of Health (IMOH) (Abraham Zangen – PI)

Role of Brain Derived Neurotrophic Factor (BDNF) within the Brain Reward System in Depressive Behavior Induced by Chronic Mild Stress. Total amount: 120,000 US $ (2010-2012).

Israel Science Foundation (ISF) (Abraham Zangen – PI)

Roles of Brain Derived Neurotrophic Factor (BDNF) and Neurogenesis on stress-induced depressive behavior and glucocorticoid secretion. Total amount: 185,000 US $ (2011-2015).

Brainsway (through BGN) (Abraham Zangen –PI)

Brain stimulation effects in animal models for depression and addiction. Total amount: 50,000 US $ (2012-2014).

BrightFocus Foundation (Abraham Zangen – PI)

Cognitive and electrophysiological effects of deep transcranial magnetic stimulation in Alzheimer patients.  Total amount: 190,000 US $ (2013-2015)

MagNet Foundation (Abraham Zangen – co-PI)

Behavioral, neurochemical and electrophysiological alterations in depression, addiction and attention deficit models following electromagnetic stimulation of the prefrontal cortex.

Total amount: 520,000 US $ (2015-2019)

Binational Science Foundation (BSF) (Abraham Zangen, Shaham Y, Heilig M – PIs)

mPFC stimulation in cocaine addiction.  Total amount: 140,000 US $ (2014-2019).

Israel Anti-Drug association (Abraham Zangen –PI).

Brain Stimulation Patterns: Electrophysiological and behavioral outcomes in an animal model for addiction and relapse.  Total amount 270,000 NIS (2016-2018).

European Commission, Horizon2020 (Abraham Zangen- local PI, Wolfgang Somer – Consortium PI).  Systems Biology of Alcohol Addiction: Modeling and validating disease state networks in human and animal brains for understanding pathophysiolgy, predicting outcomes and improving therapy. Total amount for Abraham Zangen’s projects: 240,000 Euro (2016-2019)

Israel Science Foundation (ISF) (Abraham Zangen – PI). Producing Interhemispheric Neuroplasticity in the Prefrontal Cortex to Modulate Cognition. Total amount for Abraham Zangen’s projects: 880,000 NIS (2019-2022)

The Israel Innovation Authority (KAMIN) (Abraham Zangen, Guy Doron – PIs). Combining neuromodulation and App-guided CBT to treat depression. Total amount for Abraham Zangen’s projects: 660,000 NIS (2019-2020)